

# Val J Lowe

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5082494/val-j-lowe-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

252  
papers

9,167  
citations

51  
h-index

86  
g-index

268  
ext. papers

11,913  
ext. citations

6.4  
avg, IF

6.01  
L-index

#	Paper	IF	Citations
252	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 205-216	1.2	358
251	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , <b>2016</b> , 4, 58	7.3	305
250	Age-specific population frequencies of cerebral $\beta$ amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 997-1005	24.1	246
249	Age, Sex, and APOE $\epsilon$ Effects on Memory, Brain Structure, and $\beta$ Amyloid Across the Adult Life Span. <i>JAMA Neurology</i> , <b>2015</b> , 72, 511-9	17.2	229
248	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , <b>2015</b> , 138, 1370-81	11.2	224
247	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 989-997	1.2	217
246	Remission of disseminated cancer after systemic oncolytic virotherapy. <i>Mayo Clinic Proceedings</i> , <b>2014</b> , 89, 926-33	6.4	202
245	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 540-557	8.8	198
244	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 1517-1528	11.2	194
243	Age-specific and sex-specific prevalence of cerebral $\beta$ amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 435-444	24.1	174
242	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , <b>2015</b> , 138, 761-71	11.2	173
241	Comparison of 18F-FDG and PiB PET in cognitive impairment. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 878-86		155
240	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 2091-105	5.6	149
239	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , <b>2018</b> , 141, 271-287	11.2	139
238	Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. <i>JAMA Neurology</i> , <b>2016</b> , 73, 85-92	17.2	129
237	Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. <i>Molecular Imaging and Biology</i> , <b>2005</b> , 7, 422-30	3.8	129
236	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , <b>2015</b> , 138, 3747-59	11.2	128

235	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2015</b> , 2, e161	9.1	120
234	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 2316-2325	27.4	115
233	AV-1451 tau and βAmyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , <b>2017</b> , 81, 58-67	9.4	115
232	Dementia with Lewy bodies: basis of cingulate island sign. <i>Neurology</i> , <b>2014</b> , 83, 801-9	6.5	111
231	Transplanted Senescent Cells Induce an Osteoarthritis-Like Condition in Mice. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2017</b> , 72, 780-785	6.4	111
230	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , <b>2019</b> ,	17.2	106
229	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , <b>2017</b> , 97, 143-159	3.8	105
228	[F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , <b>2017</b> , 32, 124-133	7	105
227	Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. <i>Practical Radiation Oncology</i> , <b>2018</b> , 8, 28-39	2.8	101
226	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. <i>Annals of Neurology</i> , <b>2017</b> , 82, 706-718	9.4	99
225	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , <b>2015</b> , 69, 220-36	3.8	99
224	The evolution of primary progressive apraxia of speech. <i>Brain</i> , <b>2014</b> , 137, 2783-95	11.2	99
223	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , <b>2016</b> , 132, 931-933	14.3	98
222	Association of Excessive Daytime Sleepiness With Longitudinal βAmyloid Accumulation in Elderly Persons Without Dementia. <i>JAMA Neurology</i> , <b>2018</b> , 75, 672-680	17.2	95
221	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 705-715	14.3	91
220	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , <b>2017</b> , 74, 718-726	17.2	87
219	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2096-106	5.6	85
218	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , <b>2016</b> , 15, 56-64	24.1	82

217	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 205-216	1.2	82
216	The bivariate distribution of amyloid- $\beta$ and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , <b>2019</b> , 142, 3230-3242	11.2	77
215	Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. <i>Journal of Urology</i> , <b>2015</b> , 193, 111-6	2.5	76
214	Early Postmenopausal Transdermal 17 $\beta$ Estradiol Therapy and Amyloid- $\beta$ Deposition. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 53, 547-56	4.3	70
213	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , <b>2018</b> , 75, 970-979	17.2	69
212	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , <b>2019</b> , 142, 2483-2491	11.2	62
211	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , <b>2018</b> , 184, 54-65	2.9	62
210	F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 632-638	8.9	60
209	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , <b>2014</b> , 82, 1959-675	6.5	60
208	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 21-30	5.2	57
207	Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. <i>Neurology</i> , <b>2016</b> , 86, 1128-35	6.5	55
206	The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. <i>Cancer</i> , <b>2001</b> , 92, 2341-8	6.4	54
205	18F-FDG PET of patients with H $\ddot{u}$ ttle cell carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2003</b> , 44, 1402-6	8.9	53
204	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 561-571	1.2	52
203	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , <b>2019</b> , 121, 327-337	7.5	52
202	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , <b>2016</b> , 139, 2740-2750	11.2	51
201	Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. <i>Journal of Controlled Release</i> , <b>2014</b> , 185, 121-9	11.7	50
200	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. <i>NeuroImage</i> , <b>2017</b> , 144, 113-127	7.9	49

199	Entorhinal cortex tau, amyloid- $\beta$ cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , <b>2019</b> , 142, 1148-1160	11.2	49
198	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1005-1014	1.2	47
197	[F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , <b>2018</b> , 83, 599-611	9.4	46
196	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , <b>2018</b> , 141, 1201-1217	11.2	46
195	White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1547-54	17.2	45
194	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. <i>Brain</i> , <b>2019</b> , 142, 1134-1147	11.2	44
193	Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. <i>Chest</i> , <b>2009</b> , 135, 1542-1549	4.9	44
192	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 391-8	1.2	43
191	Multimodal nanoprobe to target cerebrovascular amyloid in Alzheimer's disease brain. <i>Biomaterials</i> , <b>2014</b> , 35, 1967-76	15.6	43
190	Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. <i>Neurology</i> , <b>2013</b> , 80, 2130-7	6.5	43
189	[F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , <b>2018</b> , 83, 248-257	9.4	42
188	Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. <i>Journal of Urology</i> , <b>2017</b> , 197, 129-134	2.5	40
187	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. <i>European Urology</i> , <b>2017</b> , 71, 340-348	10.2	39
186	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , <b>2015</b> , 142, 45-53	2.9	38
185	In vivo F-AV-1451 tau PET signal in mutation carriers varies by expected tau isoforms. <i>Neurology</i> , <b>2018</b> , 90, e947-e954	6.5	37
184	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , <b>2019</b> , 93, e29-e39	6.5	36
183	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , <b>2020</b> , 2, fcaa068	4.5	36
182	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , <b>2018</b> , 90, e1404-e1412	6.5	35

181	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , <b>2019</b> , 76, 95-100	17.2	35
180	Cortical $\beta$ amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 123	8.6	34
179	Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 281-91	1.2	34
178	[Formula: see text]Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. <i>Clinical Neuropsychologist</i> , <b>2017</b> , 31, 99-117	4.4	33
177	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1713-1724	4.3	32
176	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , <b>2018</b> , 99, 358-374	3.8	31
175	$^{11}C$ -Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes. <i>Radiographics</i> , <b>2016</b> , 36, 279-92	5.4	31
174	$\beta$ Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , <b>2020</b> , 94, e282-e291	6.5	31
173	Cerebral microbleeds: Prevalence and relationship to amyloid burden. <i>Neurology</i> , <b>2019</b> , 92, e253-e262	6.5	31
172	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 927-939	1.2	30
171	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , <b>2018</b> , 84, 705-716	9.4	30
170	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2010-7	5.6	29
169	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 180-5	3.6	29
168	Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy. <i>European Urology Focus</i> , <b>2016</b> , 2, 522-531	5.1	29
167	Increased Brain Glucose Uptake After 12 Weeks of Aerobic High-Intensity Interval Training in Young and Older Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 221-227	5.6	28
166	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 97, 526-535	4	28
165	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. <i>International Psychogeriatrics</i> , <b>2018</b> , 30, 245-251	3.4	28
164	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101823	5.3	27

163	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , <b>2019</b> , 40, 1618-1631	5.9	26
162	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 739-749	5	25
161	APOE $\epsilon$ influences $\beta$ amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 630-6	1.2	25
160	Predicting future rates of tau accumulation on PET. <i>Brain</i> , <b>2020</b> , 143, 3136-3150	11.2	25
159	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 53, 1609-16	4.3	25
158	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1108-1117	17.2	25
157	Prevalence and Natural History of Superficial Siderosis: A Population-Based Study. <i>Stroke</i> , <b>2017</b> , 48, 3210-3214	6.7	24
156	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 67, 181-195	4.3	24
155	F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. <i>NeuroImage: Clinical</i> , <b>2018</b> , 18, 897-903	9.3	24
154	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , <b>2020</b> , 143, 2281-2294	11.2	23
153	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , <b>2018</b> , 141, 302-317	11.2	23
152	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 48, 3-9	3.6	22
151	Association of Apolipoprotein E $\epsilon$ 4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1913909	10.4	22
150	A robust biomarker of large-scale network failure in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 152-161	5.2	21
149	Joint associations of $\beta$ amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , <b>2018</b> , 65, 121-131	5.6	21
148	White Matter Reference Region in PET Studies of C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid- $\beta$ Deposition. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1583-1589	8.9	21
147	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 1297-1304	1.2	21
146	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , <b>2019</b> , 197, 104676	2.9	21



145	Peptide carrier-mediated non-covalent delivery of unmodified cisplatin, methotrexate and other agents via intravenous route to the brain. <i>PLoS ONE</i> , <b>2014</b> , 9, e97655	3.7	21
144	MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , <b>2019</b> , 34, 105-113	7	21
143	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , <b>2020</b> , 25, 102152	5.3	20
142	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , <b>2016</b> , 87, 691-8	6.5	20
141	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , <b>2019</b> , 86, 866-877	9.4	20
140	Cerebral microbleed incidence, relationship to amyloid burden: The Mayo Clinic Study of Aging. <i>Neurology</i> , <b>2020</b> , 94, e190-e199	6.5	20
139	Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 3323-3336	5.9	19
138	Role of $\beta$ Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1475-83	17.2	19
137	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , <b>2018</b> , 90, e940-e946	6.5	19
136	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 779-89	1.2	19
135	Comparison of [F]Flutemetamol and [C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. <i>NeuroImage: Clinical</i> , <b>2017</b> , 16, 295-302	5.3	19
134	BBBomics-Human Blood Brain Barrier Transcriptomics Hub. <i>Frontiers in Neuroscience</i> , <b>2016</b> , 10, 71	5.1	19
133	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 1019-1029	4.3	19
132	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , <b>2019</b> , 142, 2466-2482	18	18
131	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 675-685	1.2	18
130	Preparation and preliminary evaluation of $^{63}\text{Zn}$ -zinc citrate as a novel PET imaging biomarker for zinc. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1348-54	8.9	18
129	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 49, 633-43	4.3	18
128	$\beta$ Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , <b>2020</b> , 95, e3257-e3268	6.5	18



127	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , <b>2016</b> , 45, 107-108	5.6	18
126	F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , <b>2019</b> , 34, 344-352	7	18
125	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , <b>2019</b> , 85, 155-160	9.4	18
124	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 65, 1345-1352	4.3	18
123	Assessment of Lymphoma Therapy Using (18)F-FDG PET. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 1028-30	8.9	18
122	Multimorbidity and neuroimaging biomarkers among cognitively normal persons. <i>Neurology</i> , <b>2016</b> , 86, 2077-84	6.5	17
121	Clinical significance of incidental [18F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 125	3	16
120	Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 64, 281-290	4.3	16
119	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 137, 583-591	4.8	15
118	Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From F-DOPA-PET Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 1339-1346	4	15
117	First PET Imaging Studies With 63Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease. <i>Molecular Imaging</i> , <b>2016</b> , 15,	3.7	15
116	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , <b>2016</b> , 2, e85	3.8	15
115	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. <i>Brain</i> , <b>2021</b> , 144, 278-287	11.2	15
114	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , <b>2018</b> , 19, 939-947	5.3	15
113	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 355	5.3	14
112	Safety, pharmacokinetics, metabolism and radiation dosimetry of F-tetrafluoroborate (F-TFB) in healthy human subjects. <i>EJNMMI Research</i> , <b>2017</b> , 7, 90	3.6	14
111	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , <b>2017</b> , 89, 2039-2048	6.5	13
110	F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13

109	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. <i>Neurology</i> , <b>2020</b> , 94, e1793-e1802	6.5	13
108	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , <b>2016</b> , 46, 32-42	5.6	13
107	The Relationship Between Dopamine Neurotransmitter Dynamics and the Blood-Oxygen-Level-Dependent (BOLD) Signal: A Review of Pharmacological Functional Magnetic Resonance Imaging. <i>Frontiers in Neuroscience</i> , <b>2018</b> , 12, 238	5.1	13
106	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , <b>2021</b> , 31, 1693-1706	5.1	13
105	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , <b>2021</b> , 224, 117433	7.9	13
104	Association of Initial $\beta$ Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , <b>2021</b> , 78, 217-228	17.2	13
103	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. <i>Abdominal Radiology</i> , <b>2018</b> , 43, 2391-2399	3	12
102	H-MRS metabolites and rate of $\beta$ Amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , <b>2017</b> , 89, 1391-1399	6.5	12
101	Microbleeds in atypical presentations of Alzheimer's disease: a comparison to dementia of the Alzheimer's type. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 1109-17	4.3	12
100	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , <b>2020</b> , 20, 101-109	3.8	12
99	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , <b>2020</b> , 95, e23-e34	6.5	11
98	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , <b>2020</b> , 87, 556-567	9.4	11
97	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 210-216	5.2	11
96	Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1925-9	8.9	11
95	NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. <i>Neurology: Clinical Practice</i> , <b>2014</b> , 4, 470-473	1.7	11
94	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1554-1574	1.2	11
93	Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. <i>Journal of Urology</i> , <b>2018</b> , 199, 726-733	2.5	10
92	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2019</b> , 74, 877-883	6.4	10

91	Multimodal neuroimaging relationships in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 66, 56-61	3.6	10
90	Brain imaging measurements of fibrillar amyloid- $\beta$ burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE $\epsilon$ allele. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 598-609	1.2	10
89	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , <b>2021</b> , 12, 3452	17.4	10
88	Association of Longitudinal $\beta$ Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1916439	10.4	10
87	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 62-6	1.2	9
86	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 81, 34-40	3.6	9
85	Sensitivity-Specificity of Tau and Amyloid $\beta$ Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , <b>2020</b> , 88, 1009-1022	9.4	9
84	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 2274-2281	5.6	9
83	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. <i>Neurology</i> , <b>2020</b> , 94, e1571-e1579	6.5	8
82	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , <b>2016</b> , 11, 90-98	5.3	8
81	NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages. <i>Annals of Neurology</i> , <b>2021</b> , 89, 1145-1156	9.4	8
80	The influence of $\beta$ amyloid on [F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , <b>2019</b> , 92, e710-e722	6.5	8
79	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. <i>British Journal of Anaesthesia</i> , <b>2020</b> , 124, 594-602	5.4	7
78	Confirmation of I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1628-1635	8.9	7
77	Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition. <i>Neurology</i> , <b>2019</b> , 93, e2237-e2246	6.5	7
76	Initial Results of a Phase 2 Trial of F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 1383-1395	4	7
75	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2603-2611	5.5	6
74	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 707-721	5.3	6

73	High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid- Distribution between Brain and Plasma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2020</b> , 375, 308-316	4.7	6
72	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , <b>2020</b> , 20, 1115-1122	3.8	6
71	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , <b>2021</b> , 144, 3212-3225	11.2	6
70	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. <i>American Journal of Geriatric Psychiatry</i> , <b>2021</b> , 29, 179-191	6.5	6
69	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , <b>2021</b> , 89, 520-533	9.4	6
68	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , <b>2021</b> , 31, 102754	5.3	6
67	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 48	7.3	6
66	-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabc9375	17.5	6
65	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. <i>Scientific Reports</i> , <b>2018</b> , 8, 7421	4.9	5
64	Longitudinal Amyloid- $\beta$ PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 377-389	4.3	5
63	Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC). <i>Breast Cancer</i> , <b>2021</b> , 28, 1073-1086	3.4	5
62	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 136, 373-378	4.8	5
61	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , <b>2017</b> , 31, 736-743	2.5	4
60	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 390, 246-254	3.2	4
59	Esophageal cancer and head and neck cancer. <i>Seminars in Roentgenology</i> , <b>2002</b> , 37, 140-50	0.8	4
58	PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , <b>2009</b> , 114, 137-137	2.2	4
57	In Vivo Imaging and Autoradiography in a Case of Autopsy-Confirmed Pick Disease. <i>Neurology: Clinical Practice</i> , <b>2021</b> , 11, e11-e14	1.7	4
56	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , <b>2020</b> , 95, e3190-e3202	6.5	4

55	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , <b>2020</b> , 26, 259-263	0.8	4
54	Association of Cortical and Subcortical $\beta$ Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2021</b> , 33, 64-71	2.7	4
53	Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas. <i>Physics and Imaging in Radiation Oncology</i> , <b>2018</b> , 6, 94-100	3.1	4
52	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , <b>2021</b> , 238, 118259	7.9	4
51	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6376-6383	12.9	4
50	F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , <b>2020</b> , 2, fcaa040	4.5	3
49	Longitudinal flortaucipir ([F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , <b>2020</b> , 124, 33-43	3.8	3
48	Cell Therapy by Ectopic Hepatocyte Transplantation Treats the Porcine Tyrosinemia Model of Acute Liver Failure. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2020</b> , 18, 738-750	6.4	3
47	Variants in and are associated with higher tau deposition. <i>Brain Communications</i> , <b>2020</b> , 2, fcaa159	4.5	3
46	$\beta$ Amyloid PET and I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , <b>2021</b> ,	6.5	3
45	C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen $\geq 0.1$ ng/ml. <i>Journal of Cancer Research and Therapeutics</i> , <b>2021</b> , 17, 358-365	1.2	3
44	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding F-FDG-PET. <i>Brain Communications</i> , <b>2021</b> , 3, fcab182	4.5	3
43	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. <i>Brain Communications</i> , <b>2021</b> , 3, fcaa238	4.5	3
42	Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. <i>Advances in Radiation Oncology</i> , <b>2019</b> , 4, 79-89	3.3	2
41	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in : the next generation. <i>Neurocase</i> , <b>2020</b> , 26, 211-219	0.8	2
40	Longitudinal flortaucipir ([F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , <b>2020</b> , 92, 135-140	5.6	2
39	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. <i>Neurology: Genetics</i> , <b>2017</b> , 3, e201	3.8	2
38	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. <i>Brain Communications</i> , <b>2022</b> , 4, fcac017	4.5	2

37	H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults.. <i>Neurobiology of Aging</i> , <b>2022</b> , 112, 16-26	5.6	2
36	Cerebrospinal fluid dynamics and discordant amyloid biomarkers. <i>Neurobiology of Aging</i> , <b>2021</b> , 110, 27-36	6.6	2
35	Brain Metabolic Changes with Longitudinal Transcutaneous Afferent Patterned Stimulation in Essential Tremor Subjects. <i>Tremor and Other Hyperkinetic Movements</i> , <b>2020</b> , 10, 52	2	2
34	Radiation induced oxidation of [F]fluorothia fatty acids under cGMP manufacturing conditions. <i>Nuclear Medicine and Biology</i> , <b>2020</b> , 80-81, 13-23	2.1	2
33	Peripheral Markers of Neurovascular Unit Integrity and Amyloid- $\beta$ in the Brains of Menopausal Women. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 80, 397-405	4.3	2
32	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. <i>Brain Communications</i> , <b>2021</b> , 3, fcab076	4.5	2
31	Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 223-229	3.3	2
30	An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , <b>2016</b> , 26, 264-8	2.8	2
29	Amyloid- and tau-PET imaging in a familial prion kindred. <i>Neurology: Genetics</i> , <b>2018</b> , 4, e290	3.8	2
28	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , <b>2021</b> , 36, 2669-2675	7	2
27	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , <b>2021</b> , 105, 252-261	5.6	2
26	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 199	9	2
25	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , <b>2022</b> , 2, 412-424		2
24	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2019</b> , 28, 104451	2.8	1
23	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration.. <i>Brain Communications</i> , <b>2022</b> , 4, fcac013	4.5	1
22	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition.. <i>Acta Neuropathologica Communications</i> , <b>2022</b> , 10, 16	7.3	1
21	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , <b>2021</b> , 32, 102850	5.3	1
20	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , <b>2021</b> , 97, e523-e534	6.5	1



19	Cerebral Microbleeds: Relationship to Antithrombotic Medications. <i>Stroke</i> , <b>2021</b> , 52, 2347-2355	6.7	1
18	Brain amyloid, cortical thickness, and changes in activities of daily living. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 474-485	5.3	1
17	FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2021</b> , 164, 1230-1239	5.5	1
16	The value of multimodal imaging with I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , <b>2021</b> , 99, 11-18	5.6	1
15	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. <i>Neurocase</i> , <b>2021</b> , 27, 212-222	0.8	1
14	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- $\beta$ PET Signal. <i>Neurology</i> , <b>2021</b> , 97, e1799-e1808	6.5	1
13	Relationships between $\beta$ amyloid and tau in an elderly population: An accelerated failure time model. <i>NeuroImage</i> , <b>2021</b> , 242, 118440	7.9	1
12	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 108, 90-98	5.6	1
11	The Axis Promotes Inflammation-mediated Metastatic Disease in Triple-negative Breast Cancer.. <i>Anticancer Research</i> , <b>2022</b> , 42, 681-695	2.3	0
10	Prognostic role of $^{11}\text{C}$ -choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. <i>Prostate</i> , <b>2022</b> , 82, 41-48	4.2	0
9	Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. <i>Molecular Pharmaceutics</i> , <b>2021</b> , 18, 4148-4161	5.6	0
8	Neurodegeneration of the visual word form area in a patient with word form alexia. <i>Neurology and Clinical Neuroscience</i> , <b>2021</b> , 9, 359-360	0.3	0
7	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2021</b> , 50, 17-28	2.6	0
6	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	0
5	Natural COA water inhibits mitochondrial ROS-mediated apoptosis through Plk3 downregulation under STZ diabetic stress in pancreatic $\beta$ cell lines.. <i>Biochemistry and Biophysics Reports</i> , <b>2022</b> , 30, 101247	2.2	0
4	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. <i>Acta Neuropathologica</i> , <b>2022</b> , 143, 571	14.3	0
3	3D registration of micro-PET-CT for measurable correlates of dyspeptic symptoms in mice. <i>Proceedings of SPIE</i> , <b>2009</b> , 7262, 72620Z	1.7	
2	Prior Menopausal Hormone Treatments And Association of Peripheral Markers of Neurovascular Unit Integrity And $\beta$ amyloid in The Brains of Menopausal Women. <i>FASEB Journal</i> , <b>2018</b> , 32, 1b449	0.9	



1 Your brain scan may be a reflection of your genes. *Brain*, **2018**, 141, 2539-2541

11.2